Andy Billinton

SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto.

AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada.

Cigna Behavioral Health, Inc. provides healthcare services and plans. It manages behavioral health care benefits and employee assistance programs (EAPs) for health plan members nationwide. The firm's services include disability management programs for employees on short and long-term disability and referral services such as financial and legal services, childcare and eldercare. The company was founded in 1974 and is headquartered in Eden Prairie, MN.

Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California.

Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London.

Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom.

Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland.

Zeneca Pharmaceuticals manufactures medicines.

Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.

coramaze technologies GmbH operates as a medical device company which develops valve repair system. It offers mitramaze a novel concept for transcatheter mitral valve repair intended for treatment of inoperable patients suffering from severe functional mitral regurgitation. The company was founded by Laura Figulla and Till Neumann in 2013 and is headquartered in Munich, Germany.

Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom.

Cell Guidance Systems Ltd. develops tools for stem cell treatments and medical research. Its products include microvesicles, cell culture media, PODS growth factors, matrigen softwell and SINEUP. The firm also offers karyotype analysis, custom medium production, NTA profiling service and PODS proteins services. The company was founded by Michael H. Jones in 2010 and is headquartered in Cambridge, the United Kingdom.

Panakes Partners Sgr SpA (Panakes Partners) is a venture capital firm founded in 2015 by Alessio Beverina, Fabrizio Landi and Diana Sareceni. The firm is headquartered in Milan, Italy.

Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom.

Linear Diagnostics Ltd. operates as a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. It specializes in molecular diagnostics, novel technology and optical detection. The company was founded by Matt Hicks in 2011 and is headquartered in Birmingham, the United Kingdom.

Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA.

Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY.

Curve Therapeutics Ltd. operates as a drug-discovery company. It engages on the development of innovative technologies to address undruggable disease-modifying targets, with an in-house focus on cancer. The company was founded in 2019 and is headquartered in London, the United Kingdom.

Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom.

Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023.

Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom.

Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware.

Abintus Bio, Inc. operates as a preclinical stage gene therapy company. It provides immune cell reprogramming services. The company was founded by John Snyder, Nicholas A. Boyle, Douglas J. Jolly, Carlos Ibañez, Derek Ostertag, and Cory Bentley and is headquartered in Encinitas, CA.

Integra Therapeutics SL is a Spanish Barcelona-based company founded in 2020 by Marc Güell and Avencia Sánchez-Mejías, with Avencia Sánchez-Mejías serving as the CEO since then. The company is focused on engineering the next-generation of gene writing tools to cure genetic and oncological diseases with high unmet medical need. Integra Therapeutics is committed to creating new gene writing tools that improve the scope, efficiency, and safety of advanced therapies.

High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany.